EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

On November 5, 2020, a marketing authorization valid through the European Union (EU) was issued for acalabrutinib monotherapy or acalabrutinib in combination with obinutuzumab (AcalaObi) in adult patients with treatment‐naïve (TN) chronic lymphocytic leukemia (CLL) and also for acalabrutinib monothe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Delgado, Julio, Josephson, Filip, Camarero, Jorge, Garcia‐Ochoa, Blanca, Lopez‐Anglada, Lucia, Prieto‐Fernandez, Carolina, van Hennik, Paula B., Papadouli, Irene, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930415/
https://ncbi.nlm.nih.gov/pubmed/33486852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13685
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados